Vaccine for treatment of tautopathy

摘要

This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phospholylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.

主权项

1. A vaccine for treating tauopathy dementia, comprising an adeno-associated virus vector as an active ingredient,
wherein the vector comprises a nucleic acid encoding a full length mutant tau protein linked to a secretory signal sequence, wherein the full length mutant tau protein comprises a substitution mutation of an amino acid residue, P301S, at a position 301 of the amino acid sequence of SEQ ID NO: 1 of a tau protein, and wherein the vector is capable of inducing an antibody to the full length mutant tau protein in a subject in a sustained manner and the antibody being capable of reacting with phosphorylated tau protein present in the hippocampus of the subject.